Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · United Therapeutics (UTHR)

United Therapeutics enters $477.6 million ASR to complete $2 billion buyback

Neutral Impact 4 of 5 shareholder Written later

United Therapeutics entered an accelerated share repurchase agreement with Citibank to buy back about $477.6 million of its common stock, using the remainder of its $2 billion repurchase authorization. The company will pay the amount upfront on or around September 10, 2026, and will receive an initial delivery of about 719,376 shares, with final settlement expected in the fourth quarter of 2026.

Key points

  • Upfront payment of about $477.6 million to Citibank on or around September 10, 2026
  • Initial delivery of about 719,376 shares, about 75% of the shares expected under the agreement at the September 8, 2026 closing price
  • Final share count depends on the average daily VWAP during the term, less a discount; final settlement expected in Q4 2026
  • Company previously completed ASR agreements totaling $1.5 billion in March 2026 and bought $22.4 million in open-market purchases in Q3 2026

The filing

CompanyUnited Therapeutics (UTHR)
Form8-K, current report
Filed with the SECSep 8, 2026, 5:12 PM ET
Accession number0001104659-26-105953

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.